transcription, zymogen activation by proteolysis and inhibition of active forms by the tissue inhibitors of metalloproteinases (TIMPs) (Edwards et al, 1996) . There is a wealth of evidence for an association between either deregulated MMPs and aggressive/invasive behaviour in human cancers (Davies et al, 1993; Bernhard et al, 1994; Heppner et al, 1996) . This is particularly significant for gelatinase-A (MMP-2) and gelatinase-B (MMP-9) since these are critical factors in basement membrane degradation.
Gelatinase-A and gelatinase-B are controlled through distinct mechanisms. Progelatinase-A is widely expressed and is activated by a cell surface mechanism involving MT-1, -2 or -3 MMPs (Butler et al, 1997; Murphy and Knauper, 1997; Ueno et al, 1997) . In contrast, progelatinase-B is controlled primarily at the level of gene expression, its transcription being activated by mitogens and inflammatory mediators (Azzam et al, 1993; Cornelius et al, 1995; Edwards et al, 1996) . Furthermore, it is not activated by MTMMPs, but is activated more promiscuously by plasmin, stromelysin-1 and gelatinase-A . The levels of active, rather than latent, gelatinase-A correlate best with the invasive cancer phenotype (Azzam et al, 1993; Brown et al, 1993) ; in breast cancer MT1-MMP is its activator (Ueno et al, 1997) .
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas Gelatinase-A, -B and MT1-MMP are over-expressed in glioma cell lines/surgical specimens (Apodaca et al, 1990; Nakano et al, 1993 Nakano et al, , 1995 Rao et al, 1993 Rao et al, , 1996 Nakagawa et al, 1994 Nakagawa et al, , 1996 Rutka et al, 1995; Saxena et al, 1995; Sawaya et al, 1996; Uhm et al, 1996; Yamamoto et al, 1996; Forsyth et al, 1998) . Immunohistochemistry shows gelatinase-A, -B, and MT1-MMP in glioma tumour cells (Costello et al, 1994; Nakagawa et al, 1994; Rao et al, 1996; Sawaya et al, 1996; Yamamoto et al, 1996) . The distribution of gelatinase-A and -B may be different, however, in the tumour microvasculature. Some found both gelatinase-A and -B in endothelial cells (Costello et al, 1994; Rao et al, 1996; Sawaya et al, 1996) but others found only gelatinase-B in the tumour microvasculature (Nakagawa et al, 1994) . This difference in the spatial distribution suggests the function of these in gliomas may be quite different. We hypothesize that gelatinase-B may be more important in neovascularization where it may be used by capillary endothelial cells to degrade the basement membrane and allow them to migrate towards the angiogenic stimuli; endothelial cells are known to produce MMPs and TIMPs in-vitro (Hanemaaijer et al, 1993; Cornelius et al, 1995; Lewalle et al, 1995; Zucker et al, 1995; Foda et al, 1996) .
We compared the expression of gelatinase-A, -B and MT1-MMP in 47 brain tumour specimens to seven control tissues and tested the hypothesis that deregulated expression of gelatinase-A or -B, or the activator of gelatinase-A, MT1-MMP, may contribute to the aggressiveness of human gliomas. By studying these three MMPs simultaneously in a large number of the same tumour samples, we hoped to clarify their respective roles in glioma biology.
MATERIALS AND METHODS

Tissue collection
Procedures on patients were performed under a general anaesthetic and tumour specimens placed immediately in liquid nitrogen and stored at -80°C. The cervical lymph node containing the metastasis of patient no.1 was obtained at autopsy by dissection, snap frozen in liquid nitrogen and stored at -80°C. This study has the approval of our institutional ethics board. All patients gave signed, informed consent for their tissue to be used. The following tissues were studied: 19 glioblastoma multiforme (GBMs) (including two from the patients with extraneural metastases), one cervical metastasis from a GBM, five meningiomas (M), seven anaplastic astrocytomas (AA), five malignant oligodendrogliomas (MO), eight low grade gliomas (LGG), one clival chordoma and one spinal ependymoma; these were compared to seven controls (two normal brain samples obtained during non-brain tumour surgery and five from autopsy). All glioma tissue was obtained from regions of tumour corresponding to actively growing tumour; tumour regions containing only necrosis or relatively normal brain were not sampled.
Zymography
This in vitro assay uses gelatin-substrate gel electrophoresis to measure the levels of metalloproteinase activity in tumour samples. Frozen tissues were pulverized in liquid nitrogen and homogenized in buffer (0.5 M Tris-HCl, pH 7.6; 0.2 M NaCl; 10 mM CaCl 2 ; 1% Triton-X100) in an Ultra-Turrax-25 homogenizer. Ten Milligrams of total protein from homogenate supernatants were electrophoresed on 10% denaturing sodium dodecyl sulphate (SDS) polyacrylamide gels containing 1 mg ml -1 of gelatin. Gels were washed overnight in washing buffer (50 mM Tris-HCI; pH 8.0; 5 mM CaCl 2 ; 2.5% Triton-X100) and then incubated for 24 h at 37°C in the above buffer without Triton-X100 so that renaturation of enzyme could occur. Gels were stained with Coomassie blue and de-stained. Gelatinolytic activities were visualized as clear bands against a blue background. Gels were analysed by computerized densitometric scanning of the images using a Hewlett-Packard Scan Jet IIc Scanner, Deskscan II software and the NIH 'Image' Program. The size and intensity of each band were determined and its area plotted on graphs.
RT-PCR
RNA preparation
Total RNA was extracted from cells by the acid guanidinium isothiocyanate method. The final RNA concentrations were determined by absorption using a GeneQuant spectrophotometer (Pharmacia).
Reverse transcription reactions
Each 20 µl cDNA synthesis reaction contained 1 µg of total RNA, 1 × PCR buffer (10 mM Tris-HCl; pH 9.0; 50 mM KCl; 1.5 mM magnesium chloride), 1 mM each of deoxynucleotide triphosphates (dATP, dGTP, dCTP, and dTTP), 20 units placental ribonuclease inhibitor (RNAguard, Pharmacia), 200 units of MuLV-reverse transcriptase (RT) (Bethesda Research Laboratories) and 100 pmol of random hexamer oligodeoxynucleotides (Pharmacia). Reaction mixtures were preincubated 10 min at 21°C prior to cDNA synthesis. The reverse transcription reactions were carried out for 50 min at 42°C and were heated to 95°C for 5 min to terminate the reaction. Samples were cooled to 4°C or stored at -20°C until use.
PCR reactions
Multiplex PCRs were performed in 50 µl reaction volumes. Each reaction contained 2 µl of RT reaction product as template DNA (corresponding to cDNA synthesized from 100 ng of total RNA), 1 × PCR buffer, 80 µm of each deoxynucleotide (in addition to the dNTP left over from the RT reaction, resulting in a final concentration of approximately 180 µM) and 20 pmol each of 5′ and 3′ target primers. Two units of Taq DNA polymerase (Gibco-BRL) were added to each tube during the first denaturation step ('hot start') and equal aliquots (20 pmol) of GAPDH primer sets were added at the appropriate cycle number by the 'primer dropping' method (Wong et al, 1994) . Each PCR cycle consisted of a heatdenaturation step at 94°C for 1 min, a primer-annealing step at 55°C for 30 s, and a polymerization step at 72°C for 1 min. PCR amplifications were performed in a Temp-Tronic Thermal Cycler (Barnstead/Thermolyne). Aliquots of PCR reaction products (approximately 10 µl) equalized to give equivalent signals from the internal control mRNA (GAPDH) were electrophoresed through 2% agarose gels containing 0.2 mg of ethidium bromide. To allow quantification of RT-PCR data, an initial 'cycle test' was performed for each sample and primer set to determine the appropriate number of cycles required for detection of amplification products while remaining in the exponential phase of PCR. For gelatinase-A, gelatinase-B and MT1-MMP amplifications, the operative cycle numbers were 29, 33 and 30 respectively. GAPDH primers were added to the last 23 cycles. Gels were illuminated with UV light, photographed using Polaroid film, and analysed by computerized densitometric scanning as described above. The intensities of the ethidium bromide fluorescence signals were determined from the area under the curve for each peak and the data were plotted on graphs.
The following primers were employed:
The size of the amplification products were 473 bp for gelatinase-A, 454 bp for gelatinase-B, 548 bp for MT1-MMP and 306 bp for GAPDH respectively.
In situ hybridization for gelatinase-A, -B and MT1-MMP mRNA
A 348 bp Bgl-BamHI fragment of human gelatinase-A (sequence corresponding to 1404-1752) was obtained by RT-PCR from human Hs68 cell RNA and cloned into pBluescript KS-(Stratagene). The construction of the 390 bp gelatinase-B probe has been described previously (Urbanski et al, 1992) . The MT1-MMP probe was a 420 bp region encompassing the pro-domain and part of the catalytic domain, cloned in pBluescript SK+ based on the sequence of Sato et al (1994) and generously provided by Dr Suneel Apte, Cleveland Clinic Foundation, Cleveland, OH, USA. For gelatinase-A, antisense riboprobe was generated with T3 polymerase from template linearized with XbaI, and sense riboprobe was produced with T7 polymerase and BamHI-cut plasmid.
Corresponding probes for gelatinase-B involved: T7 polymerase and HindIII-cut template (antisense), T3 polymerase and NotI-cut template (sense). For MT1-MMP, we used T3 polymerase and SalI-cut template (anti-sense); T7 polymerase and EcoRI-cut plasmid (sense). Riboprobes were prepared and labelled with digoxygenin (DIG)-labelled-UTP (Boehringer Mannheim, Laval, Quebec, Canada) following the manufacturer's instructions. Confirmation of sense and antisense riboprobe was confirmed by Northern blot analysis. Antisense probes but not sense probes, detected a single band of the appropriate size for all three genes. In situ hybridization was performed as described previously (Harvey et al, 1995; Leco et al, 1997) . Briefly, 4-µm paraffinembedded brain sections were dewaxed in xylene and rehydrated through a series of graded ethanols. Sections were treated with proteinase K (20 µg ml -1 ), acetylated and then prehybridized in buffer containing 50% formamide, 5 × SSPE, 1 × Denhardt's solution, 20 mM DTT for 6 h at 50°C. Hybridization was done at 60°C overnight in the same buffer to which 20 ng ml -1 of probe and 8 µg ml -1 of Escherichia coli tRNA were added. After hybridization, sections were then washed once in 2 × SSC at 37°C, treated with 20 mg ml -1 RNase A at 37°C, washed once in 2 × SSC at 50°C, once in 50% formamide at 50°C, twice in 2 × SSC at 50°C and once in 0.5 × SSC at 50°C; all for 30 min each time. Following blocking, sections were incubated in a 1:1000 dilution of sheep anti-DIG-alkaline phosphatase conjugated antibody (Boehringer Mannheim), for 4 h at room temperature. After extensive washing, NBT/BCIP chromogens were applied to sections and colour was developed in the dark until the desired intensity was obtained. The reaction was terminated by placing sections in 20 mM Tris-HCl, pH 7.5, 10 mM EDTA. Sections were then dipped briefly in water, counter-stained for 3 min in 0.02% fast green, washed for 1 min in water and mounted with Advantage aqueous mounting medium (Accurate Chemical). The slides were photographed on Kodak Royal Gold 35 mm film using a Zeiss photomicroscope II under bright-field illumination.
Statistical analysis
The quantitative expression of gelatinase-A and -B in terms of lysis per mg of protein from the zymograms, or in terms of their transcript intensity for gelatinase-A, -B and MT1-MMP from RT-PCR were compared using the Kruskal-Wallis test. These quantitative expressions were correlated with glial malignancy (normal low grade versus malignant glioma versus GBM) using Spearman's rank correlation coefficient. Data for meningiomas and other brain tumours were plotted but not analysed statistically.
RESULTS
Detection of gelatinase-A, -B, and MT1-MMP mRNA by RT-PCR analysis
Gelatinase-A, -B and MT1-MMP mRNA expression was evaluated by RT-PCR and compared with frozen samples of histologically defined normal brain tissue and brain tumours (Figure 1) . Gelatinase-A, -B and MT1-MMP RNA expression was very low in the normal samples. PCR amplification of cDNA prepared from frozen samples defined histologically as low grade glioma (oligodendroglioma, astrocytoma, oligo-astrocytoma, pilocytic
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MT-MMP1 GAPDH Figure 1 Representative examples of expression of gelatinase-A, -B and MT1-MMP mRNA using RT-PCR in human brain tumour and normal brain tissue. Two control samples have low levels of transcripts of all three genes. Tumour levels of gelatinase-A and MT1-MMP were higher than in normal tissues and varied somewhat but did not strongly correlate with tumour malignancy. Gelatinase-B RNA levels were also variable but were much higher in GBMs than in low grade gliomas. Higher levels of gelatinase-A and MT1-MMP than gelatinase-B RNAs were seen in meningiomas. Abbreviations for all Figures: AA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; CLN-1 = cervical lymph node metastasis; ENM = extraneural metastasis; GBM = glioblastoma multiforme; GBM-1, -2 = first and second GBM patient with extramural metastases; LGG = low grade glioma; MO/MA = malignant oligodendroglioma or malignant astrocytoma; N1-7 = normal tissue; Other = 1 clival chordoma and 1 spinal ependymoma; RA = reactive astrocytes astrocytoma), malignant gliomas (anaplastic astrocytomas or malignant oligodendroglioma), glioblastoma, meningioma, or other (clival chordoma or spinal ependymoma) demonstrated the presence of gelatinase-A, -B and MT1-MMP transcripts; these were consistently over-expressed in tumour samples compared to normal tissues. Expression of gelatinase-A and MT1-MMP was highly variable and did not correlate with degree of glioma malignancy (r = 0.2024 Spearman's rank correlation coefficient, P = 0.2185 and r = 0.2406 Spearman's rank correlation coefficient, P = 0.1436 respectively) (Figure 2 ). In contrast, gelatinase-B RNA levels were also variable but correlated more strongly with glioma malignancy with higher levels seen in higher grades (r = 0.4453 Spearman's rank correlation coefficient, P = 0.0068). Though few meningiomas were studied, there were very high levels of gelatinase-A and MT1-MMP expression. Of the four tumour specimens showing the highest levels of gelatinase-B expression, two were from patients whose tumours subsequently had extraneural metastases and a third from a patient whose GBM eroded through his skull (Table 1) ; both are very rare events.
Zymographic analysis
The activities of gelatinase-A and -B in human brain tumours and normal tissue were analysed by gelatin zymography. The latent form of gelatinase-A (72 kDa) was detected in almost every tissue extract. Low levels of both gelatinase-A and -B activity were found in the control specimens and these were similar to the activities seen in low grade gliomas. Progelatinase-A levels were highly variable within each tumour type and correlated with the degree of tumour malignancy (r = 0.4091 Spearman's rank correlation coefficient, P = 0.0061) (Figures 3 and 4) . We found active gelatinase-A only in the two patients who had extraneural metastases from their GBM and in the cervical extraneural metastasis itself in one patient. Progelatinase-A was high or intermediate in meningiomas. For gelatinase-B there was a trend for higher levels of activity to be seen in more malignant gliomas; levels were highest in GBMs, and consistently higher than activities in controls or low grade gliomas (r = 0.3543 Spearman's rank correlation coefficient, P = 0.018). Gelatinase-B activity was much lower than gelatinase-A in meningiomas (see Figure 4) .
Localization of gelatinase-A, -B and MT1-MMP mRNA in normal brain and human brain tumour tissues
The identity of cells expressing gelatinase-A, -B and MT1-MMP was determined by in situ analysis of paraffin-embedded sections. As observed in our analysis above, gelatinase-A and MT1-MMP were expressed in very low, but detectable, levels in normal brain tissue, most prominently in neurons with much less signal in glial cells and blood vessels. In tumours, gelatinase-A and MT1-MMP were expressed in the tumour cells and in many cell types in the surrounding stroma, including neurons, glia and blood vessels ( Figure 5A-F) . Gelatinase-B expression ( Figure 5G-I ) was present at very low levels in normal tissues (principally neurons in the hippocampus; Figure 5G and data not shown) but in the tumours it was largely restricted to regions in blood vessels that were undergoing endovascular proliferation at the infiltrating border of the tumour ( Figure 5H, I ). For most tumours studied there was no detectable staining of gelatinase-B in tumour cells themselves, in the rest of the surrounding stroma, or in blood vessels in other areas that were not proliferating, such as the centre of the tumour. However, in three other patients the pattern of expression was more diffuse and gelatinase-B expression was present in all cell types in the tumour.
These in situ hybridization data can be summarized as follows:
1. Expression of gelatinase-A and MT1-MMP showed close correspondence. Both were present in neurons in normal brain, and in both tumour and stromal cell types in tumour. Though in situ hybridization is not quantitative, signals were weak in normal brain, but usually strong in tumours, indicating a general concordance with the RT-PCR data in Figure 1 .
2. Gelatinase-B was also weakly expressed in neurons in normal brain, but in contrast to gelatinase-A and MT1-MMP its expression in tumours was most evident in proliferating blood vessels at tumour margins. Some tumours showed endothelial cell positivity for gelatinase-B transcripts, while the example shown in Figure 5 had pronounced expression in surrounding cell types which are likely vascular smooth muscle cells or pericytes.
DISCUSSION
The significance of the present work rests on several key points. Firstly, this is the largest study undertaken to date on primary human brain tumour specimens to assess the role of MMPs, and the first to simultaneously evaluate the contributions of gelatinase-A, gelatinase-B and MT1-MMP in a common set of brain tumour specimens. Secondly, our results show that although all three MMPs are likely connected in some way with malignant behaviour in gliomas, gelatinase-B is the most closely correlated with tumour grade. Thirdly, we provide the first in situ hybridization data to localize the cellular origins of MMP expression in gliomas. These studies lead to the notion that gelatinase-B is primarily involved in tumour neovascularization, wheras the widespread and similar localization of gelatinase-A and MT1-MMP mRNAs suggests involvement in both invasion and angiogenesis. Our in situ hybridization results show that the transcripts of gelatinase-A, -B and MT1-MMP have different cellular origins. Gelatinase-A and MT1-MMP were both expressed by many cell types in gliomas, including the microvasculature and the tumour cells themselves (Costello et al, 1994; Yamamoto et al, 1996; Sawaya et al, 1996) . We observed expression of both gelatinase-A and MT1-MMP RNAs mostly in neurons in normal tissue, with low signals from blood vessel elements. This suggests that an important contribution of the increased expression of gelatinase-A and MT1-MMP in malignant gliomas compared to normal brain relates to neovascularization at tumour margins and blood vessel expansion deep within the tumour. The other component of increased gelatinase-A and MT1-MMP expression is the tumour cells themselves, which confirms other immunolocalization work Sawaya et al, 1996) .
The restricted perivascular localization of gelatinase-B expression by in situ hybridization agrees with immunodetection of gelatinase-B Nakagawa et al, 1994) . In some tumours we observed gelatinase-B in endothelial cells and tumour cells but in others we found expression confined to cells lying deep to the vessel endothelium. These are most likely pericytes and/or smooth muscle cells and angiogenesis involves cooperation between these (Folkman, 1971; Hirschi and D'Amore, 1996) . Pericyte/vascular smooth muscle cell (VSMC) proliferation has been suggested to be an early event in microvascular proliferation in GBMs (Wesseling et al, 1995) where it may be critical for new vessel formation (Wesseling et al, 1995; Haddad et al, 1992) . Gelatinase-B expression may be associated with early rapid pericyte proliferation during angiogenesis and later during vessel growth expression is taken over by endothelial cells themselves.
Several changes in gene expression in the tumour and the surrounding vasculature must occur to induce neovascularization (Hanahan & Folkman, 1996) . Evidence that MMP activity is required for neovascularization includes observations that TIMPs and synthetic MMP inhibitors block angiogenesis in a number of experimental systems (Rosenthal et al, 1994; Johnson et al, 1994; Schnaper et al, 1993; Taraboletti et al, 1995) ; though some (Thorgeirsson et al, 1996) suggest the anti-angiogenic activities of TIMP-1 may not be mediated by its anti-metalloproteinase effects. Inhibition of MMP activity using a synthetic inhibitor GM6001 has also been shown to block smooth muscle cell migration in vivo which may also contribute to the antiangiogenic actions of these molecules (Bendeck et al, 1996) . Our demonstration that gelatinase-B expression is localized to the vasculature at the proliferating borders in gliomas provides further support for the importance of MMPs in angiogenesis.
We provide further support for the notion that in gliomas the MMPs gelatinase-A and MT1-MMP are both produced and used by the tumour cells themselves Costello et al, 1994; Nakagawa et al, 1994; Yamamoto et al, 1996; Sawaya et al, 1996) . While it would seem intuitively obvious that tumour cells would produce MMPs in many systemic cancers it is the surrounding non-tumoural stromal cells that produce them (Heppner et al, 1996; Pyke et al, 1993; Poulsom et al, 1993) . One explanation for the differences in cellular expression of MMPs in gliomas versus in systemic cancers may be the nature of the specialized 'stroma' in the brain. Systemic cancers are often confined by tough basement membranes and collagen-rich tissue whereas the brain's ECM is composed chiefly of hyaluronan and proteoglycans (Giese and Westphal 1996) . In addition to posing a less formidable barrier to invasion the brain's stromal environment may regulate proteinase expression in glioma cells.
Malignant gliomas, and GBMs in particular, are both highly invasive and vascular tumours and our results suggest that both of these processes depend in part on the increased expression of gelatinase-A, MT1-MMP and gelatinase-B. Changes in the expression patterns of several MMPs might be important in different human brain tumours at different times in their malignant progression. For example, gelatinase-A may be expressed at an early stage in tumorigenesis and support glioma invasion but gelatinase-B may be employed at later stages in malignant progression to help provide and maintain tumour vasculature. The mechanisms underlying the upregulation of these MMPs in gliomas are unknown and need to be better understood. This would provide important information about the regulatory pathways controlling glioma invasion and angiogenesis and suggest appropriate targets for clinical therapies.
